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IMPORTANCE There have been concerns raised by patients and regulatory agencies regarding

Supplemental content

serious psychiatric adverse effects associated with 5α-reductase inhibitors.
OBJECTIVE To determine if there is an increased risk of suicide, self-harm, or depression
among older men starting a 5α-reductase inhibitor for prostatic enlargement.

CME Quiz at
jamanetwork.com/learning

DESIGN, SETTING, AND PARTICIPANTS A population-based, retrospective, matched cohort
study using linked administrative data for 93 197 men ages 66 years or older (median [IQR]
age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a
5α-reductase inhibitor during the study period (2003 through 2013). Participants were
matched (using a propensity score that included 44 of our 96 covariates that included
medical comorbidities, medication usage, and health care system utilization) to an equal
number of men not prescribed a 5α-reductase inhibitor.
EXPOSURES Duration of finasteride or dutasteride usage.
MAIN OUTCOMES AND MEASURES Suicide. Secondary outcomes were self-harm and

depression.
RESULTS Men who used 5α-reductase inhibitors were not at a significantly increased risk of
suicide (HR, 0.88; 95% CI, 0.53-1.45). Risk of self-harm was significantly increased during the
initial 18 months after 5α-reductase inhibitor initiation (HR, 1.88; 95% CI, 1.34-2.64), but not
thereafter. Incident depression risk was elevated during the initial 18 months after
5α-reductase inhibitor initiation (HR, 1.94; 95% CI, 1.73-2.16), and continued to be elevated,
but to a lesser degree, for the remainder of the follow-up period (HR, 1.22; 95% CI, 1.08-1.37).
The absolute increases in the event rates for these 2 outcomes were 17 per 100 000
patient-years and 237 per 100 000 patient-years, respectively. The type of 5α-reductase
inhibitor (finasteride or dutasteride) did not significantly modify the observed associations
with suicide, self-harm, and depression.
CONCLUSIONS AND RELEVANCE In a large cohort of men ages 66 years or older, we did not
demonstrate an increased risk of suicide associated with 5α-reductase inhibitor use.
However, the risk of self-harm and depression were increased compared with unexposed
men. This is in keeping with postmarketing experience and patient concerns, and
discontinuation of the medication in these circ umstances may be appropriate.

JAMA Intern Med. 2017;177(5):683-691. doi:10.1001/jamainternmed.2017.0089
Published online March 20, 2017.

Author Affiliations: Department of
Surgery, Western University, London,
Ontario, Canada (Welk); Institute for
Clinical Evaluative Sciences, London,
Ontario, Canada (Welk, McArthur,
Anderson, Hayward, Dixon);
Department of Epidemiology and
Biostatistics, Western University,
London, Ontario, Canada (Welk,
Anderson, Dixon); Division of
Urology, Department of Surgery,
University of Toronto, Toronto,
Ontario, Canada (Ordon).
Corresponding Author: Blayne Welk,
MD, MSc, Department of Surgery and
Epidemiology and Biostatistics,
Western University Room B4-667,
St Joseph's Health Care 268
Grosvenor Street, London, ON N6A
4V2, Canada (bkwelk@gmail.com).

(Reprinted) 683

Copyright 2017 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ by a Western University User on 09/01/2022

Research Original Investigation

Association of Suicidality and Depression With 5α-Reductase Inhibitors

B

enign prostatic hyperplasia (BPH) is a major contributor to lower urinary tract symptoms (LUTS) in older
men. Symptoms are found in approximately onequarter of men over 70 years.1 Guidelines from American, Canadian, and European urology societies recommend a 5αreductase inhibitor (5ARI) as medical therapy for BPH related
LUTS.2-4 As a medication class, 5ARIs target the 5α-reductase
enzyme family, which is responsible for transforming steroid
precursors into active hormones.5 This includes the conversion of testosterone to dihydrotestosterone, which accounts
for the use of 5ARIs for androgenic alopecia and BPH.5 Among
BPH patients, 5ARIs reduce prostate volume, LUTS, and future BPH-related complications and surgery.6,7 There are 2
equally efficacious 5ARI medications available for the treatment of BPH 8 : finasteride (which inhibits type 2 5αreductase) and dutasteride (which inhibits both type 1 and type
2 5α-reductase).
The potential adverse neurologic effects of these medications are an emerging area of concern. In 2011 the United States
Food and Drug Agency (FDA) received a postmarketing submission suggesting that self-harm and suicide may be associated
with finasteride use, and may persist after discontinuation of
the medication.9 Health Canada recently identified similar
concerns.10 An analysis of the FDA Adverse Event Reporting System found a disproportionately high rate of suicidal ideation reported among men taking finasteride for alopecia.11 Postmarketing experience resulted in the addition of depression to the
5ARI product monographs. Two prior clinical studies12,13 (a secondary analysis of a randomized trial and a cross-sectional study
of patients with BPH) suggested there is an increased risk of depression associated with 5ARI use. There is ancillary evidence
supporting a potential relationship between 5ARIs and suicidality or depression. First, 5α-reductase is responsible for the production of several neuroactive steroids.5,14 Second, testosterone and dihydrotestosterone modulate the neuroendocrine
stress response and are inversely related to depression
indices.15-18 Third, levels of the neurosteroid allopregnanolone (produced by 5α-reductase) are lower among men with
depression.19,20 Finally, patients with clinical depression have
lower levels of type I 5α-reductase in the prefrontal cortex.18
To date, very little research has assessed the potential risks
of suicidality and depression from 5ARI medications, despite
concerns from regulatory agencies and plausible underlying
biologic mechanisms. Our objective was to conduct a population-based retrospective study among older men to assess for
a potential relationship between 5ARI use and suicide, selfharm, and depression.

Methods
Design and Setting
We conducted a retrospective, matched-cohort study using existing population-based data from the province of Ontario in
Canada. Patient-level data was linked using unique encoded
identifiers and analyzed at the Institute for Clinical Evaluative Sciences. A deterministic, patient-level record linkage process was used. Ontario is Canada’s largest province (popula684

Key Points
Question Is the use of 5α-reductase inhibitors for the treatment
of benign prostatic hyperplasia associated with a risk of suicide,
self-harm behavior, or depression?
Findings Using a matched cohort design and population-based
data, 5α-reductase inhibitors were not found to be associated with
an increase in suicide. However, the risk of self-harm and
depression were significantly increased, primarily during the first
18 months after initiation of the medication.
Meaning The risk of self-harm and depression should be
considered when prescribing 5α-reductase inhibitors. In patients
presenting with thoughts or evidence of self-harm, or with a new
diagnosis of depression, the continued use of this medication
should be reevaluated.

tion of 12.9 million people at study midpoint) and the entire
population has access to a single health care system. Universal medication coverage is provided for those 65 years or older.
This study was approved by the institutional review board at
Sunnybrook Health Sciences Centre, Toronto, Ontario, and individual patient consent was not required. The study protocol is included in Supplement 1. Study reporting follows the
STROBE/RECORD guidelines for observational studies using
routinely collected data (eTable 1 in Supplement 2).21

Data Sources
We used several administrative data sources for this study: (1)
Registered Persons Database (containing vital statistics),22 (2)
Ontario Drug Benefit database (containing all prescription drug
use for Ontarians older than 65 years),23 (3) Canadian Institute for Health Information Discharge Abstract Database (identifying all inpatient admissions and procedures, and inpatient psychiatric care prior to 2005),24 (4) National Ambulatory
Care Reporting System (identifying all emergency department encounters),25 (5) Ontario Health Insurance Plan (containing all physician billing and diagnostic codes for patient
assessment or treatment),26 (6) Ontario Registrar GeneralDeath database (containing the manner and cause of death),27
and (7) Ontario Mental Health Reporting System (containing
records of all inpatient psychiatric care from 2005 onwards).28
Our study variables were complete, aside from less than 0.4%
missing data for socioeconomic status and rurality (these patients were retained for analysis).

Patient Population
Using the unique drug identification numbers in the Ontario
Drug Benefit Database (which has greater than 99% accuracy
in prior validation studies)23 we identified a cohort of men
66 years or older who filled their first prescription for finasteride or dutasteride between January 1, 2003 and December
30, 2013 (exposed men). The prescription fill date was considered the index date for the patient, and the beginning of
the observation period. All remaining men in the province of
Ontario during the study period (unexposed men) were
assigned a random index date based on the distribution of
index dates among the exposed men. Within both groups,
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we conducted standard data cleaning steps, and then
excluded men who had used a 5ARI in the 2 years prior to
2003, those who used multiple 5ARIs on their index date,
those who were younger than 66 years, those without any
prescription in the prior 3 months in the Ontario Drug Benefit Database, and those who were in hospital or visited an
emergency department in the 2 days prior to the index date
(to limit the potential confounding of serious concurrent
medical illness). Further details are shown in eFigure 1 in
Supplement 2.
We matched men with a 5ARI prescription to those without any 5ARI prescriptions, based on their index date (within
1 year), a history of depression or self-harm in the 5 years prior
to the index date, evidence of antidepressant medication usage in the 6 months prior to the index date, and the logit of a
propensity score. We assessed 96 different covariates, representing medical and psychiatric comorbidities, medication usage, and health care utilization (coding definitions and lookback windows are detailed in eTable 2A-C in Supplement 2).
Qualitative variables were analyzed as categorical variables.
Among the 96 measured covariates, 44 were selected for inclusion in the propensity score based on standardized differences of 7% or greater or a high likelihood of confounding (further details in eTable 3 in Supplement 2).

Study Outcomes
We prespecified suicide as our primary outcome. Our a priori
hypothesis was that suicide would be significantly higher
among men exposed to 5ARIs. All cases of unnatural death in
Ontario are investigated by a coroner (who is a licensed physician); deaths with clear evidence of suicidal intent29 are registered as a suicide on the death certificate by the coroner and
entered in the Ontario Registrar General-Death database. There
is good inter-rater agreement among Ontario coroners for relevant mechanisms of suicide.30 Our secondary outcomes were
self-harm, and incident depression (determined using a validated definition).31 Self-harm included both emergency department visits for a suicide attempt or parasuicide behavior,
and psychiatric hospital admission for recent self-harm or
thoughts of self-harm. To identify incident cases of depression, patients with an existing history of depression in the 5
years prior to the index date were excluded for the analysis of
this outcome. Details of the data sources, diagnostic codes, and
validity of these outcomes are presented in eTable 4 in
Supplement 2.
We observed patients for our study outcomes during an
at risk period, which was defined as continuous medication
usage plus 12 months. Continuous usage started on the day the
prescription was filled, and continued for the prescription duration; it was extended for the duration of each follow-up prescription that was filled within 1.5 × the number of days of previous prescription supply.32 The 12-month post-5ARI period
was included owing to the possible persistence of symptoms
after the discontinuation of the 5ARI medication.33,34 Patients were allowed to switch among 5ARI medications during this at risk period, and on discontinuation of the 5ARI the
patient was not reentered in the cohort if they restarted a 5ARI
in the future.

Original Investigation Research

Statistical Analysis
Baseline characteristics were compared using standardized differences (SD); an SD greater than 10% was considered a potentially important difference.35 We used greedy matching (1:1
without replacement) and a caliper of 0.2 standard deviations of the logit of the propensity score.36
Our primary analysis was completed using SAS statistical
software (version 9.4, SAS institute). Stratified Cox proportional hazards models were used to account for matching and
to censor matched pairs based on the end of the at risk period, or when either member of the pair reached a specified
outcome, died, emigrated from the province, or reached the
end of the study period (December 31, 2013). The Cox proportional hazards model assumption of proportionality was assessed statistically using a time-dependent covariate, and
graphically using Schoenfeld residuals. When proportionality was violated, the model was stratified based on fixed time
periods after the index date so that proportionality was restored. Hazard ratios (HRs) and 95% CIs are reported (and the
SAS program and output for the primary analysis is included
in the eAppendix in Supplement 2), as well as absolute risk.
Secondary outcomes were assessed using similar methodology. Three preplanned secondary analyses were conducted.
First, we included probable suicide cases in the primary outcome definition (eTable 4 in Supplement 2). Second, 3 potential effect modifiers were assessed (prior depression, prior selfharm, and recent antidepressant usage). Finally, results were
stratified by type of 5ARI. The statistical significance of the latter 2 secondary analyses was assessed by adding an interaction term in the model. Two posthoc analyses were performed: outcome models were repeated after matched pairs
with a history of prostate cancer (a potential confounder)37
were excluded, and a competing risk model (using Fine and
Gray’s method)38 for nonsuicide mortality was used for our primary and secondary outcomes. For all analyses, we considered 2-tailed P values less than .05 statistically significant.

Results
Cohort selection is presented in eFigure 1 in Supplement 2. After matching we retained 93 197 pairs. Baseline characteristics of the matched exposed and unexposed men that are particularly relevant to our study are presented in Table 1
(complete covariates are presented in eTable 5 in Supplement
2). Acknowledged risk factors for suicide in the elderly,39,40
such as mental illness, chronic medical conditions (seizure,
neurologic disease, cancer), depression, substance abuse, and
prior self-harm episodes were very well balanced between cohorts, and no standardized differences greater than 8% persisted in our final matched cohort for any of the covariates. The
index 5ARI was dutasteride for 48 505 (52.0%), and finasteride for 44 692 (48.0%) of men. Dosage, duration of use ,and
index prescriber specialty are described in eTable 6 in
Supplement 2.
The absolute risk of suicide was very low in both exposed
and unexposed men (0.04%), and there was no significantly
increased HR among men exposed to 5ARI medications (HR,
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Table 1. Relevant Baseline Characteristics for the Cohort of Men Exposed to 5ARIs and the Cohort
of Matched Unexposed Mena
No. (%)
Characteristic

Unexposed (n = 93 197)

Exposed (n = 93 197)

Standardized
Difference, %

Demographics
Age

75 (70-81)

75 (70-80)

5

Socioeconomic quintile
1 (Lowest)

15 773 (16.9)

15 740 (16.9)

0

5 (Highest)

21 279 (22.8)

21 163 (22.7)

0

0

69 788 (74.9)

71 555 (76.8)

4

1

8510 (9.1)

8705 (9.3)

1

2

8263 (8.9)

6609 (7.1)

7

≥3

6636 (7.1)

6328 (6.8)

1

Charlson-Deyo Comorbidity Score

Medical history
Acute urinary retention
Benign prostatic hyperplasia
Cancer

9683 (10.4)

9397 (10.1)

1

62 977 (67.6)

59 474 (63.8)

8

5977 (6.4)

2

Alcoholism

739 (0.8)

723 (0.8)

0

Anxiety

426 (0.5)

445 (0.5)

0

Bipolar disorder

115 (0.1)

98 (0.1)

0

Depression

6480 (7)

3353 (3.6)

3353 (3.6)

0

Schizophrenia and/or delusional
disorder

178 (0.2)

163 (0.2)

0

Self-harm

191 (0.2)

191 (0.2)

0

Substance abuse

144 (0.2)

142 (0.2)

0

Medication utilization
Antidepressants
SSRI and/or SNRI

7306 (7.8)

7057 (7.6)

1

Other

5909 (6.3)

6229 (6.7)

2

Typical

2277 (2.4)

2127 (2.3)

1

Atypical

712 (0.8)

687 (0.7)

Antipsychotics

Benzodiazepines
Mood stabilizers
Narcotics

12 254 (13.1)

12 216 (13.1)

957 (1.0)

943 (1.0)

1
0
0

15 790 (16.9)

15 693 (16.8)

0

92 589 (99.3)

92 536 (99.3)

0

Psychiatric health care utilization
Psychiatric hospitalizations
0
≥1

608 (0.7)

661 (0.7)

0

Family physician mental health visits
0

81 428 (87.4)

81 312 (87.2)

1

≥1

11 769 (12.6)

11 885 (12.8)

1

90 417 (97)

90 316 (96.9)

1

2881 (3.1)

1

Psychiatry visits
0
≥1

2780 (3.0)

0.88; 95% CI, 0.53-1.45) (Table 2). The addition of probable suicide cases identified only a few additional outcomes, and did
not change our model results significantly.
Our secondary outcomes of self-harm and incident depression violated our statistical test and graphical assessment of proportionality (eFigure 2 in Supplement 2). Selfharm required 3 separate time periods and depression required
2 separate time periods to maintain proportionality (each time
period has its own hazard ratio). Among men exposed to 5ARIs,
686

Abbreviations: 5ARI, 5α-reductase
inhibitor; SNRI, serotoninnorepinephrine reuptake inhibitor;
SSRI, selective serotonin reuptake
inhibitor.
a

All results are median (interquartile
range) or number (proportion). The
complete list of 96 covariates is
provided in eTable 5 in
Supplement 2.

there was a significantly increased hazard of self-harm (HR,
1.88; 95% CI, 1.34-2.64) and depression (HR, 1.94; 95% CI, 1.732.16) during the first 18 months of use (Table 2). The hazard
for self-harm was not significantly elevated after the initial 18
months, whereas the hazard for depression was lower in
magnitude but still significantly elevated for the remainder
of the follow-up period (HR, 1.22; 95% CI, 1.08-1.37). The
Kaplan-Meier curves for self-harm and depression, stratified
by 5ARI use, are included in eFigure 3 in Supplement 2. The
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Self-Harm (Secondary Outcome)

[Reference]

1.07 (0.64 to 1.77)e

Nonsignificant P values ⱖ.10.

P values < .01.

NA

[Reference]

[Reference]

[Reference]

[Reference]

f

+236.5

+0.58% (0.46 to 0.70)

1.22 (1.08 to 1.37)f

1.22 (1.08 to 1.37)f

1.94 (1.73 to 2.16)f

NA

530.1 (501.1-560.3)

1.60 (1.01-3.48)

232 226

1231 (1.37%)

89 844 Non-5ARI Users

e

NA

766.6 (731.3-803.2)

1.57 (1.00-3.38)

228 274

1750 (1.95%)

Men were considered at risk for the outcomes during their initial continuous period of 5ARI usage, and for 12 months after discontinuing the medication; men could be censored earlier based on death or emigration.

NA

Depression (Secondary Outcome)
89 844 5ARI Usersb

The secondary outcomes of self-harm and depression did not meet the assumption for proportional hazards, and as such the results were stratified by follow-up time.

+17.24

+0.04% (+0.01 to +0.08)

[Reference]

[Reference]

e

0.63 (0.36 to 1.09)

[Reference]

1.88 (1.34 to 2.64)f

NA

53.47 (44.85-63.28)

1.62 (1.02-3.53)

243 121

130 (0.14%)

93 197 Non-5ARI Users

d

NA

70.71 (60.63-81.99)

1.58 (1.00-3.43)

239 106

169 (0.18%)

93 197 5ARI Users

c

All results are median (interquartile range) or number (%), with 95% confidence intervals.

Matched pairs with a prior history of depression were excluded from the cohort for this analysis.

[Reference]

b

−1.10

[Reference]

NA

NA

NA

[Reference]

14.79 (10.52-20.26)

1.62 (1.02-3.53)

243 377

36 (0.04%)

93 197 Non-5ARI Users

a

Change in event rate
(per 100 000)
Abbreviation: NA, not applicable.

0% (−0.02 to +0.02)

NA

1.5-3 years

Change in absolute risk

NA

0.88 (0.53-1.45)e

15.89 (11.40-21.58)

1.59 (1.00-3.43)

239 217

38 (0.04%)

93 197 5ARI Users

Death by Suicide (Primary Outcome)

0-1.5 years

Stratifiedd

Overal

Hazard ratio

Event rate (per 100 000)

Median (IQR) years of at risk
follow-upc

Patient-years of exposure

No. (%)

Characteristic

Table 2. Risk of Suicide, Self-Harm, and Depression Among Men Exposed to 5ARI Medications Compared With Matched Unexposed Mena
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Table 3. Primary and Secondary Outcomes Stratified by Initial 5ARI Type
Events/No. at Risk (%)
Outcome

5ARI Users,
Exposed Cohort

HR
Non-5ARI Users,
Unexposed Cohort

Overall HR

Stratified HR
(0-1.5 Years)

Stratified HR
(>1.5 Years)
NA

Suicide
Dutasteride

16/48 505 (0.03)

11/48 505 (0.02)

1.20 (0.52-2.78)

NA

Finasteride

22/44 692 (0.05)

25/44 692 (0.06)

0.74 (0.40-1.38)

NA

NA

NA

NA

P value for
interactiona

NA

NA

.36

Self-harm
Dutasteride

81/48 505 (0.17)

60/48 505 (0.12)

NA

1.96 (1.22-3.15)

0.77 (0.43-2.38)

Finasteride

88/44 692 (0.20)

70/44 692 (0.16)

NA

1.80 (1.10-2.94)

0.89 (0.55-1.44)

P value for
interactiona

NA

NA

NA

.80

.72

Dutasteride

825/46 895 (1.76)

541/46 895 (1.15)

NA

2.00 (1.71-2.34)

1.24 (1.03-1.49)

Finasteride

925/42 949 (2.15)

688/42 949 (1.60)

NA

1.87 (1.59-2.19)

1.20 (1.02-1.41)

P value for
interactiona

NA

NA

NA

Depression

.53

.80

Abbreviations: HR, hazard ratio; NA, not applicable.
a

The interaction P value represents whether there is a significant difference in the outcome based on the type of 5ARI.

self-harm outcome represented an actual suicide attempt or
parasuicide behavior in 58% (75/130) of unexposed men and
57% (96/169) of exposed men. When considering only this subset of self-harm patients, the HR during the first 18 months was
still significantly increased (HR, 1.61; 95% CI, 1.04-2.48;
P = .03). Of the men with self-harm during the study period,
6.9% (9/130) unexposed and 5.9% (10/169) exposed men later
died of suicide during our defined at risk period.
In our secondary analysis, the potential effect modifiers
did not have a significant statistical interaction with our primary outcome of suicide (prior history of depression, P = .32;
active depression, P = .56) (eTable 7 in Supplement 2). The prior
self-harm subgroup was too small to fit to a statistical model.
Stratification of our primary and secondary outcomes by initial type of 5ARI did not reveal any significant differences in
the primary or secondary outcomes (Table 3). Posthoc, the
model excluding men with a prior history of prostate cancer
(eTable 8 in Supplement 2), and the model accounting for the
competing risk of nonsuicide mortality (eTable 9 in Supplement
2) both had similar results to our primary analysis of suicide,
self-harm and depression.

Discussion
We conducted a population-based retrospective cohort study
of approximately 186 000 men ages 66 years or older to assess for concerning psychiatric problems potentially associated with 5ARIs. We did not demonstrate a significant increase in the risk of suicide among older men using 5ARIs for
BPH, and prior depression or antidepressant use did not modify
this result. The rate of suicide among men exposed to 5ARIs,
and similar men not exposed to 5ARIs was approximately 15
of 100 000 person years in both groups (in keeping with a yearly
suicide rate of 19 of 100 000 Ontario males ages 60 or older).41
However, we did demonstrate a significantly increased risk of
688

self-harm (for the initial 18 months after initiation of a 5ARI),
and new diagnoses of depression (throughout follow-up)
among men exposed to 5ARI medications. The initial increased risk, which attenuates for both outcomes after 18
months, is in keeping with an acute change associated with the
initiation of a 5ARI. These significant differences were consistent among both the finasteride and dutasteride users. Depression in elderly persons is associated with reduced functioning and quality of life, increased health care utilization, and
a chronic and relapsing course.42,43 Although the absolute risk
of self-harm is low, this is still potentially important given the
increasing rate of self-harm in adults,44 the high costs associated with subsequent treatment,45 and the strength of this as
a risk factor for future self-harm and suicide.46,47 Several theories have been proposed to explain the transition from selfharm thoughts to self-harm behavior to completed suicide.48
Because we only measured outcomes with a temporal relationship to 5ARI use, the discontinuation of the 5ARI may have
occurred prior to some men dying from suicide, or this may
have prevented further self-harm. Alternatively, there may have
been effective interventions after an episode of self-harm which
reduced the risk of progression to suicide.
Two secondary analyses of a randomized, placebocontrolled clinical trial49 evaluating finasteride for prostate cancer prevention are relevant to our study. Moinpour et al50 demonstrated that there was no difference in mental health
domains over 7 years of finasteride use, however when Unger
et al12 linked a subset of trial patients to Medicare claims, they
found a modest increase in depression among the finasteride
users (HR, 1.10; 95% CI, 1.01-1.19). A cross-sectional survey13
of 4035 Polish men with BPH measured a 1.5 fold increased frequency of depressive symptoms among men using 5ARIs. The
majority of other research in this area focuses on young men
taking finasteride for alopecia. A case series51 in 2002 reported on 19 patients with alopecia who developed moderate
to severe depression with finasteride use. Among men who
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sought treatment for persistent adverse effects after the discontinuation of finasteride, 1 mg, there were high rates of depression, and suicidal thoughts, although there is an obvious
selection bias in these studies, and some of these findings may
be explained by preexisting psychiatric problems.33,34,52

Strengths and Limitations
We used a retrospective, matched-cohort design and measured 96 relevant covariates, of which 44 were included in a
propensity score. We carefully considered the validity of our
primary and secondary study outcomes (eTable 4 in
Supplement 2), and censored patients to limit their risk period to ensure there was a temporal association between our
exposure and outcomes. Finally, our exposure was defined
using the Ontario Drug Benefit database, which has considerable accuracy.23 Limitations of our study include the possibility of misclassification of key study variables, and residual confounding. Nondifferential misclassification of our outcomes
is likely to have occurred given their measurement characteristics, (and would generally bias our results toward the null).53
The true incidence of suicide was likely underestimated, given
the limited sensitivity of coroner records for identifying suicide, and depression can be both overdiagnosed and underdiagnosed in the elderly population.30,40,42,54 Residual confounding is a consistent limitation of any observational study,
and while the propensity score accounts for many defined variables, there are covariates (such as family history of suicide and
psychosocial supports)39,46,55 that were not measured; however, they are unlikely to be differentially distributed based on
5ARI use. Furthermore, surveillance and the propensity for a
patient to be diagnosed with self-harm and depression may
have been different after the initiation of the 5ARI. It is possible there is a small but significant association between suicide and 5ARI usage which we were unable to detect with our
sample size (our 95% CI suggests a true HR between 0.53 and
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1.45 is possible). Lower urinary tract symptoms themselves may
be related to depression, or may lower a patient’s quality of life
and therefore lead to depressive symptoms.56 We tried to adjust for this by matching on a history of depression, and balancing recent use of an α antagonist or overactive bladder medication, and prior BPH diagnosis or transurethral prostate
surgery. Finally, medication compliance was not directly measured, although, given a median duration of use of approximately 12 months, it is unlikely that men would be refilling a
prescription they were not taking.

Implications
The recognition of depression and self-harm as potential adverse effects of 5ARIs is important given their significant impact. However, the relatively small magnitude of these risks
should not dissuade physicians from prescribing these
medications in appropriate patients. This research may help
physicians counsel patients on the risks of 5ARIs. Discontinuation of the 5ARI may be appropriate in the setting of newonset depression or self-harm after the initiation of a 5ARI.51
The outcomes from this study need to be assessed in younger
men using finasteride for alopecia. A foundation dedicated to
studying the adverse effects of finasteride speaks to the interest among patients in this research topic.57

Conclusions
The risk of suicide was not significantly elevated in men ages
66 years or older using 5ARIs for BPH, however the risks of selfharm and incident depression were significantly increased, primarily during the first 18 months after the initiation of either
finasteride or dutasteride. The absolute increased risk of these
2 outcomes was low, and the potential benefits of 5ARIs in this
population likely outweigh these risks for most patients.
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Invited Commentary

The Risk of Suicidality and Depression
From 5-α Reductase Inhibitors
Stephen Thielke, MD, MS

The Scottish philosopher David Hume observed a fundamental incompatibility between factual and moral propositions,
known as Hume’s Law: that facts are not the basis for right and
wrong, or, put another way, that “should” cannot be derived
from “is.” Clinicians constantly face this problem, even if they
are unconscious of it: striving do the morally right thing on the
basis of factually right knowledge, yet depending ultimately
on the patient’s and their own ideas of what is Good as a means
to establish a goal. Scientific advances may thus complicate
moral decision-making.
In this issue of JAMA Internal Medicine, the findings reported by Welk et al1 about mental health effects of 5-α reductase inhibitors (5ARIs) illustrate this dilemma. The authors discovered, using more precise methods than in any previous
research, a clear association
between 5ARI prescription
Related article page 683
and some negative mental
health outcomes among older
men with lower urinary tract symptoms (LUTS). Comparing
5ARI users and carefully matched nonusers, there was no difference in risk of suicide. Risk of self-harm was increased by
17 per 100 000 patient-years, but only during the first 18
months of treatment. Risk of incident depression was increased by 272 per 100 000 patient-years, with a mitigated risk
after 18 months. Based on these numbers, clinicians would occasionally encounter patients with depression, and would very
rarely encounter cases of self-harm, that could be attributed
to 5ARIs.
What ought a clinician to do with these findings? Some options include (1) prescribing other medications for LUTS that
are not known to increase risk of depression, (2) giving clear
warning to all patients about the possible risks, (3) warning
those who have had prior depression about the risks, (4) monitoring carefully for depression during 5ARI use, or (5) doing
nothing, insofar as the absolute differences in risk were small
and the events rare. Hume’s Law posits that the facts about
5ARIs and depression do not in themselves inform what should
be done. Instead, to get to “should,” one must introduce some
conception of the desired outcome: doing no harm, increasing some specific aspect of quality of life, reducing rates of mental illness, maximizing patient autonomy, following treatment guidelines, minimizing polypharmacy, ensuring patient
satisfaction, avoiding malpractice, or some other aim. Even per-

fect knowledge about the mechanisms, risks, and benefits of
a treatment will not direct either the clinician or patient toward what they want to accomplish. Because some of these
aims conflict with others, there is no way to accomplish them
all at once, and a moral decision must be made between them,
even if no one acknowledges that this occurred.
A key conundrum is weighing dissimilar hypothetical conditions: potentially worsening mood or self-harm behavior vs
potentially improved urinary tract symptoms. Lower urinary
tract symptoms and depressive symptoms can have significant effects on health-related quality of life, but in a complex
way. Mental health variables seem to mediate the relationship between LUTS and quality of life,2 so causation is unclear. More problematically, there is no common currency for
the utility value of not having depression or LUTS, in real or
hypothetical form. “Quality of life,” as a measurable construct, is almost always defined by researchers rather than patients, and patients may have other frameworks for characterizing a good life. Even when patient-reported outcomes are
assessed,3 it is unclear if patients and researchers are applying the same standards of desirable and undesirable states or
outcomes.
This point may seem of purely academic interest, but medication adherence patterns provide striking evidence of its centrality in clinical care. In the current study, during 6 years of
follow-up, the median duration of 5ARI use was 1 year (as seen
in the supplementary table in the article by Welk et al1). This
corresponds with other research about high 5ARI discontinuation rates,4 as well as adherence rates to other prescribed
medications. Although the reasons were not specified, it seems
clear that very many patients with LUTS voted with their feet
and chose not to continue the medications, despite numerous scientific articles touting their benefits, and professional
guidelines recommending their ongoing use. Depression and
self-harm would account for but a sliver of the discontinuation, and it seems likely that patients found other reasons to
stop. The level of patient concern is evident in a patient foundation established to study adverse effects of one 5ARI. Its website enumerates numerous “life-altering” and “devastating”
“sexual, neurological, and physical side effects” in postfinasteride syndrome.5 Are clinicians under an obligation to mention this possible effect when prescribing finasteride? Are they
obligated to discuss research about the apparent benefits of
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